retatrutide developer eli lilly ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial retatrutide #elililly #retatrutide #weightloss #obesitycare

Each step up delivers roughly three additional percentage points

This subjective measure correlates surprisingly well with medication effectiveness and helps identify when dose adjustments might be needed

Metabolic effects beyond weight loss Both cagrilintide and retatrutide affect metabolic parameters far beyond the number on the scale

It was not a major reason for discontinuation in the trial, but it represents a side effect category that tirzepatide users do not encounter

To better understand current usage levels, near-term growth potential, and behavioural shifts among users, Leger surveyed 1,536 Canadians and 1,012 Americans

Consult a qualified healthcare professional before starting supplements, especially if you have health conditions or take medications